



Giselle (Ghazal) Salmasi, MD

Clinical Associate Professor, Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **Stanford Comprehensive Cancer Center**

875 Blake Wilbur Dr Clinic F

Breast Cancer Clinic

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 725-9113

Bio

BIO

Dr. Salmasi is a board-certified, fellowship-trained hematologist. She treats patients in the Hematology Program and the Hematologic Cancer Program at Stanford Health Care. Dr. Salmasi is the associate clinical chief for classical hematology. She is also a clinical associate professor in the Division of Hematology, Department of Medicine at Stanford University School of Medicine.

She treats a wide range of blood disorders and blood cancers. Her clinical/research interests include immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). Dr. Salmasi understands that patients need social and emotional support along with medical care. She founded the earliest adolescent and young adult survivorship support groups in Santa Cruz, California, and Toronto, Canada. Dr. Salmasi is also dedicated to training future doctors in providing excellent hematologic care.

Dr. Salmasi was the medical co-investigator for a national phase 3 clinical trial of endovascular therapy for treating chronic venous thrombosis.

Her research has appeared in the New England Journal of Medicine, Leukemia & Lymphoma journal and the Transfusion and Apheresis Science journal. Dr. Salmasi's publications include articles and a chapter about lymphoma. She has also reviewed articles for the Biology of Blood and Marrow Transplantation journal and the Journal of Clinical Oncology.

Dr. Salmasi is a member of the American Society of Hematology.

CLINICAL FOCUS

- Hematology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Hematology

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2019)
- Fellowship: University of Toronto Faculty of Medicine (2013) Canada
- Residency: University of Toronto (2011) ON Canada
- Medical Education: McMaster University Michael G. DeGroot School of Medicine (2007) Canada

Publications

PUBLICATIONS

- **Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.** *Blood*
Sekrecki, M., Sekrecka, A., Lattupally, R. R., Le, K., Jin, X., Mozes, C., Dwyer, B. G., Zhuang, Z., Romero, B. A., Pineda, J. M., Cao, X., Nguyen, L., Chen, et al
2026
- **Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16**
Sekrecki, M., Sekrecka, A., Lattupally, R., Le, K., Cao, X., Chen, V., Zhuang, Z., Dwyer, B., Zhou, C., Tiwari, C., Gabel, A., Kim, W., Stanley, et al
ELSEVIER.2025: 1474-1475
- **More on Monoclonal Gammopathy of Thrombotic Significance. Reply.** *The New England journal of medicine*
Salmasi, G., Murray, D. L., Padmanabhan, A.
2024; 391 (15): 1464
- **More on Monoclonal Gammopathy of Thrombotic Significance Reply** *NEW ENGLAND JOURNAL OF MEDICINE*
Salmasi, G., Murray, D. L., Padmanabhan, A.
2024; 391 (15): 1464
- **Myeloma Therapy for Monoclonal Gammopathy of Thrombotic Significance.** *The New England journal of medicine*
Salmasi, G., Murray, D. L., Padmanabhan, A.
2024; 391 (6): 570-571
- **Acquired factor VII inhibitor associated with primary central nervous system Lymphoma: A case report.** *EJHaem*
Goyal, V., Salmasi, G., Leavitt, A. D., Rubenstein, J. L., Banerjee, R.
2022; 3 (3): 1000-1002
- **From cardiogenic shock to dual organ transplants: managing heparin-induced thrombocytopenia with therapeutic apheresis and IVIG** *ASAIO Journal*
Wu, Y., Baudart, S., Abad, A. J., Cheng, R., Salmasi, G., Klein, L.
2022
- **Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution**
Schoenbeck, K. L., Cerejo, M., Cornett, P. A., Damon, L. E., Gaensler, K. L., Leavitt, A. D., Logan, A. C., Mannis, G. N., Olin, R. L., Salmasi, G., Sayre, P. H., Shah, N. P., Dhruva, et al
AMER SOC HEMATOLOGY.2019
- **Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms**
Schoenbeck, K. L., Salmasi, G., Cerejo, M., Cornett, P. A., Damon, L. E., Logan, A. C., Olin, R. L., Leavitt, A. D., Smith, C. C.
AMER SOC HEMATOLOGY.2019
- **Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab.** *Leukemia & lymphoma*
Salmasi, G., Li, M., Sivabalasundaram, V., Panzarella, T., Tsang, R., Kukreti, V., Crump, M., Kuruvilla, J.
2015; 56 (6): 1659-64
- **Trimming the fat with an IVIG approval process.** *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*
Chow, S., Salmasi, G., Callum, J. L., Lin, Y.
2012; 46 (3): 349-52

- **Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses.** *Acta obstetricia et gynecologica Scandinavica*
Salmasi, G., Grady, R., Jones, J., McDonald, S. D.
2010; 89 (4): 423-441
- **Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species.** *Cerebrospinal fluid research*
Johnston, M., Zakharov, A., Papaiconomou, C., Salmasi, G., Armstrong, D.
2004; 1 (1): 2